Five Top US Hospitals Adopt 4DMedical’s CT:VQ™ Within Five Months of FDA Clearance
4DMedical has secured a commercial contract with University of Chicago Medicine to deploy its CT, VQ™ lung imaging technology, marking the fifth major US academic medical centre to adopt the platform since FDA clearance.
- University of Chicago Medicine expands partnership to include commercial CT, VQ™ deployment
- Fifth leading US academic medical centre to adopt CT, VQ™ within five months of FDA clearance
- Initial prepaid scan package included in the commercial contract
- CT – VQ™ enhances assessment and procedural planning in complex lung diseases
- 4DMedical’s rapid commercialisation strategy validated by multiple elite medical centres
A Strategic Expansion in Lung Imaging
4DMedical Limited (ASX, 4DX) has announced a significant expansion of its partnership with University of Chicago Medicine, a top-ranked US hospital renowned for pulmonology and lung surgery. The agreement now includes the commercial deployment of 4DMedical’s CT, VQ™ technology, a cutting-edge lung imaging solution that combines ventilation and perfusion analysis to provide detailed functional insights.
This development marks the fifth prestigious US academic medical centre to adopt CT, VQ™ since its FDA clearance less than five months ago, joining the ranks of Stanford, Cleveland Clinic, UC San Diego Health, and University of Miami. The rapid uptake among these elite institutions underscores the technology’s clinical value and the effectiveness of 4DMedical’s commercialisation approach.
Clinical Advantages and Early Adoption
University of Chicago Medicine has been an early adopter of 4DMedical’s respiratory imaging portfolio, including the XV Lung Ventilation Analysis Software (XV LVAS™). The expanded agreement now incorporates a commercial contract featuring an initial prepaid scan package designed to accelerate clinical deployment of CT, VQ™. While this initial package is not financially material, it positions UChicago Medicine as a key opinion leader with significant potential to scale usage as clinical workflows mature.
Professor Kyle Hogarth, Director of Bronchoscopy at UChicago Medicine, has highlighted the clinical benefits of CT, VQ™ in managing complex lung diseases. The technology’s ability to assess regional ventilation and perfusion from routine CT scans enhances procedural planning and ongoing patient management, offering a more nuanced understanding of conditions such as COPD and small airways disease.
Commercial Momentum and Market Positioning
4DMedical’s Managing Director and CEO, Andreas Fouras, emphasised the significance of this expanded partnership, describing UChicago Medicine as a pioneer in medical innovation. The rapid adoption of CT, VQ™ by five leading academic medical centres within months of FDA approval validates the company’s strategy and strengthens its position in the competitive respiratory imaging market.
Combined with its partnership with Philips and a growing commercial pipeline, 4DMedical is building momentum to establish CT, VQ™ as the new standard of care in pulmonary imaging. The company’s software-as-a-service model integrates seamlessly into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care.
As 4DMedical advances through 2026, the expanded use of CT, VQ™ at influential sites like University of Chicago Medicine will be critical to demonstrating the technology’s transformative potential and driving broader clinical adoption.
Bottom Line?
With five top US centres onboard, 4DMedical’s CT, VQ™ is poised to reshape pulmonary imaging standards.
Questions in the middle?
- How quickly will University of Chicago Medicine scale CT – VQ™ usage beyond the initial prepaid scans?
- What impact will 4DMedical’s partnership with Philips have on accelerating commercial adoption?
- How will CT, VQ™ compete with existing lung imaging technologies in broader clinical settings?
